Navigation Links
Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria
Date:6/29/2011

ROCKVILLE, Md., June 29, 2011 /PRNewswire-USNewswire/ -- Sanaria's mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against malaria caused by Plasmodium falciparum and P. vivax. In the process of developing these vaccines, Sanaria has developed the capacity to manufacture and assay malaria parasites and mosquitoes in a highly regulated, cGMP compliant, industrial setting. These parasites, mosquitoes, and assay services are now available to the general research community as Sanaria Inc. announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology.

Sanaria® Plasmodium falciparum Sporozoite Reagents:  Aseptic, purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium falciparum (Pf) sporozoites.

Sanaria® PfSPZ Challenge Mosquitoes:  Live, aseptic and non-aseptic P. falciparum infected mosquitoes. These well-characterized mosquitoes are for experimentally challenging volunteers in studies assessing malaria vaccines and drugs and for laboratory-based research.

Sanaria® Plasmodium Reagents:  Purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium species sporozoites, as well as other life cycle stages for laboratory-based research studies.  

Sanaria® Plasmodium Reagent Slides: Slides for immunofluorescence assays to detect antibodies against purified sporozoite, and asexual erythrocytic, sexual erythrocytic and/or mosquito stages of Plasmodium species.

Sanaria® Anopheles Reagents: Aseptic and non-aseptic Anopheles stephensi mosquitoes and derived material for laboratory-based research studies.

Sanaria® Plasmodium Assay Services: Assessment of the effects of antibodies and drugs on the capacity of P. falciparum and P. vivax sporozoites to invade and develop in hepatocytes (inhibition of sporozoite invasion and inhibition of liver stage development assay), and of P. falciparum gametocytes to develop to oocysts and sporozoites in mosquitoes (transmission blocking assay). Assessment of antibodies to all life cycle stages of Plasmodium species by immunofluoresence assays and to selected antigens by ELISA.

Monoclonal Antibodies: Sporozoite, liver, and blood stage monoclonal antibodies.

Sanaria® Custom Services: Sanaria will manufacture Plasmodium species reagents to meet your specifications.

For more information please visit www.sanaria.com. For pricing and other information please e-mail sales@sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Public Relations Contact: arichman@sanaria.com Investor Contact: rcthompson@sanaria.com


'/>"/>
SOURCE Sanaria Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
2. The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria
3. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
4. Malaria: New Treatment is Upcoming
5. Mosquito genes linked to insecticide resistance may be new target in fight against malaria
6. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
7. Chimerix Joins International Network of Organizations to Cure Malaria
8. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
9. GenVec Expands Contract Supporting Malaria Vaccine Program
10. First genetically engineered malaria vaccine to enter human trials
11. Discovery provides new drug targets for malaria cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
Breaking Biology Technology:
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):